It’s very sad to see hype like this. They only had 30 enrolled, this was just a safety study, and while the data looks promising, there is certainly not enough statistical power, which is why there is no approval yet.
Shame on the BBC. If you are going to quote invesigators, you should state that they have paid consultancy deals with UniQure.
The same two people were equally excited about a Roche therapy years ago…
But UniCure stock went up 200% today, which is the point.
It’s very sad to see hype like this. They only had 30 enrolled, this was just a safety study, and while the data looks promising, there is certainly not enough statistical power, which is why there is no approval yet.
Shame on the BBC. If you are going to quote invesigators, you should state that they have paid consultancy deals with UniQure. The same two people were equally excited about a Roche therapy years ago…
But UniCure stock went up 200% today, which is the point.
Even if they saved a single person it’d be statistically significant.